Trial Profile
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2022
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Acronyms ValEAR
- 22 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Aug 2020 Planned number of patients changed from 108 to 52.
- 20 Oct 2018 Status changed from not yet recruiting to recruiting.